Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Pharmaceutical firm Bristol Myers Squibb invested an undisclosed amount in US-based programmable cell therapy developer ArsenalBio yesterday through a collaboration deal focusing on T cell therapies to treat solid tumours. The partnership deal includes a $70m upfront payment and it comes after ArsenalBio launched in October 2019 with $85m in series A funding from investors including Westlake Village BioPartners, Parker Institute for Cancer Immunotherapy, Kleiner Perkins, University of California, San Francisco Foundation Investment Company, Euclidean Capital and Osage University Partners.
…
